Table 4 The 5-year overall survival rate of patients with both genes co-expression

a

Beclin-1++/PCNA++

2

0

0

b

Beclin-1++/PCNA+

20

13

65.0

b vs. c

P=0.008

c

Beclin-1+/PCNA++

18

3

16.7

b vs. d

P=0.025

d

Beclin-1+/PCNA+

63

19

30.2

C vs. d

P>0.05

e

Beclin-1++/NET-1++

5

2

40.0

E vs. f

P>0.05

f

Beclin-1++/NET-1+

17

11

64.7

f vs g

P=0.000

g

Beclin-1+/NET-1++

32

4

12.5

h vs g

P=0.003

h

Beclin-1+/NET-1+

49

18

36.7

f vs h

P=0.046

i

Beclin-1++/Bcl-2++

1

0

0

j

Beclin-1++/Bcl-2+

21

13

61.9

J vs k

P=0.000

k

Beclin-1+/Bcl-2++

10

1

10.0

J vs l

P=0.029

l

Beclin-1+/Bcl-2+

71

21

29.6

l vs k

P=0.015

m

Beclin-1++/Bax++

5

5

100.0

n

Beclin-1++/Bax+

17

8

47.1

n vs. o

P>0.05

o

Beclin-1+/Bax++

10

7

70.0

n vs. p

P>0.05

p

Beclin-1+/Bax+

71

15

21.1

o vs. p

P=0.010

q

Beclin-1++/MVD++

1

1

100.0

r

Beclin-1++/MVD+

21

12

57.1

r vs. s

P=0.000

s

Beclin-1+/ MVD++

33

3

21.2

r vs. t

P=0.043

t

Beclin-1+/ MVD+

48

15

31.3

s vs. t

P>0.05